Skip to main content
Fig. 3 | BMC Gastroenterology

Fig. 3

From: PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis

Fig. 3

Greater fibrosis burden at baseline, as defined by Ludwig fibrosis stage or hepatic collagen content by morphometry, was associated with a significantly increased risk of disease progression among noncirrhotic patients with PSC in the phase 2 simtuzumab study. Disease progression was defined by progression to cirrhosis (F4), ascending cholangitis, hepatic decompensation, liver transplantation, or death. [15] p values by log-rank test

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us